Market closed
Pasithea Therapeutics Corp./$KTTA
Pasithea Therapeutics shares are trading higher after a safety review committee recommended continuing its Phase 1 trial of PAS-004 in advanced cancer.
14 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
Ticker
$KTTA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
4
Website
KTTA Metrics
BasicAdvanced
$3.2M
-
-$12.69
0.75
-
Price and volume
Market cap
$3.2M
Beta
0.75
52-week high
$2.34
52-week low
$0.92
Average daily volume
3.5M
Financial strength
Current ratio
6.58
Quick ratio
6.182
Management effectiveness
Return on assets (TTM)
-42.23%
Return on equity (TTM)
-72.83%
Valuation
Price to book
0.11
Price to tangible book (TTM)
0.26
Price to free cash flow (TTM)
-0.093
Growth
Earnings per share change (TTM)
-2.51%
3-year earnings per share growth (CAGR)
44.80%
KTTA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Pasithea Therapeutics Corp. stock?
Pasithea Therapeutics Corp. (KTTA) has a market cap of $3.2M as of April 16, 2025.
What is the P/E ratio for Pasithea Therapeutics Corp. stock?
The price to earnings (P/E) ratio for Pasithea Therapeutics Corp. (KTTA) stock is 0 as of April 16, 2025.
Does Pasithea Therapeutics Corp. stock pay dividends?
No, Pasithea Therapeutics Corp. (KTTA) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Pasithea Therapeutics Corp. dividend payment date?
Pasithea Therapeutics Corp. (KTTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Pasithea Therapeutics Corp.?
Pasithea Therapeutics Corp. (KTTA) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.